- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological treatment of hyperglycemia in type 2 diabetes
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 131, Issue 2, Pages -
Publisher
American Society for Clinical Investigation
Online
2021-01-19
DOI
10.1172/jci142243
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The therapeutic potential of second and third generation CB1R antagonists
- (2020) Resat Cinar et al. PHARMACOLOGY & THERAPEUTICS
- Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
- (2020) Habib Yaribeygi et al. Journal of Diabetes Research
- Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
- (2020) Suzanne V. Arnold et al. CIRCULATION
- Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
- (2020) Basem M Mishriky et al. DIABETES & METABOLISM
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
- (2020) John B. Buse et al. DIABETES CARE
- Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users
- (2020) Morten Hasselstrøm Jensen et al. DIABETES CARE
- Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
- (2020) Xilin Zhou et al. DIABETES CARE
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
- (2020) Simeon I. Taylor DIABETES CARE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans
- (2019) Franz M. Matschinsky et al. Frontiers in Physiology
- Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
- (2019) Ralph A DeFronzo et al. Diabetes & Vascular Disease Research
- Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
- (2019) Amber L. Beitelshees et al. DIABETES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do GLP‐1RA and SGLT‐2i reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
- (2019) Basem M Mishriky et al. DIABETES OBESITY & METABOLISM
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
- (2019) David R Matthews et al. LANCET
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- GDF15 mediates the effects of metformin on body weight and energy balance
- (2019) Anthony P. Coll et al. NATURE
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- Cardiovascular outcome trials of diabetes drugs: lessons learned
- (2018) Simeon I. Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
- (2018) Anila K. Madiraju et al. NATURE MEDICINE
- Dulaglutide and renal protection in type 2 diabetes
- (2018) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- GLP-1 receptor agonists: differentiation within the class
- (2018) Simeon I Taylor Lancet Diabetes & Endocrinology
- Changes of Cell Biochemical States Are Revealed in Protein Homomeric Complex Dynamics
- (2018) Bram Stynen et al. CELL
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
- (2017) Hung-Wei Liao et al. BMJ Open
- Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
- (2016) Rachel J. Perry et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
- (2016) Robert J. Smith et al. DIABETES CARE
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
- (2016) Kaixin Zhou et al. NATURE GENETICS
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
- (2015) Jeremy T. Warshauer et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin Pharmacogenomics: Current Status and Future Directions
- (2014) A. C. Pawlyk et al. DIABETES
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
- (2014) Alex M. DePaoli et al. DIABETES CARE
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Insulin Receptor Signaling in Normal and Insulin-Resistant States
- (2014) J. Boucher et al. Cold Spring Harbor Perspectives in Biology
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
- (2013) Renato D. Lopes et al. AMERICAN HEART JOURNAL
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial
- (2013) Kenneth W. Mahaffey et al. AMERICAN HEART JOURNAL
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
- (2013) C. F. Burant DIABETES CARE
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- (2013) D. M. Nathan et al. DIABETES CARE
- Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
- (2013) Russell A. Miller et al. NATURE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
- (2013) J. Michael Gaziano et al. Journal of the American Heart Association
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- (2012) P. Fouqueray et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
- (2012) Charles F Burant et al. LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
- (2011) G. E. Meininger et al. DIABETES CARE
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
- (2010) J. Calles-Escandon et al. DIABETES CARE
- Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
- (2010) R. A. DeFronzo et al. DIABETIC MEDICINE
- Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes
- (2010) Fredrick L. Dunn et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Lipid-induced insulin resistance: unravelling the mechanism
- (2010) Varman T Samuel et al. LANCET
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
- (2008) L. Van Gaal et al. DIABETES CARE
- Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
- (2008) S. E. Kahn et al. DIABETES CARE
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started